These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38730287)

  • 1. The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.
    Wumener X; Zhang Y; Zang Z; Du F; Ye X; Zhang M; Liu M; Zhao J; Sun T; Liang Y
    BMC Pulm Med; 2024 May; 24(1):227. PubMed ID: 38730287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of net influx constant based on FDG PET/CT dynamic imaging in the differential diagnosis of metastatic from non-metastatic lymph nodes in lung cancer.
    Wumener X; Zhang Y; Zang Z; Ye X; Zhao J; Zhao J; Liang Y
    Ann Nucl Med; 2024 Nov; 38(11):904-912. PubMed ID: 39078558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic FDG-PET imaging for differentiating metastatic from non-metastatic lymph nodes of lung cancer.
    Wumener X; Zhang Y; Wang Z; Zhang M; Zang Z; Huang B; Liu M; Huang S; Huang Y; Wang P; Liang Y; Sun T
    Front Oncol; 2022; 12():1005924. PubMed ID: 36439506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
    Ding CY; Yang WP; Guo Z; Sun J; Li YY; Li TR
    Zhonghua Zhong Liu Za Zhi; 2017 Jul; 39(7):528-531. PubMed ID: 28728300
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantitative CT density histogram values and standardized uptake values of FDG-PET/CT with respiratory gating can distinguish solid adenocarcinomas from squamous cell carcinomas of the lung.
    Tsubakimoto M; Yamashiro T; Tamashiro Y; Murayama S
    Eur J Radiol; 2018 Mar; 100():108-115. PubMed ID: 29496067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of (18)F-FDG PET-CT imaging to predict epidermal growth factor receptor mutations in patients with lung squamous cell carcinoma].
    Zhao CY; Deng XY; Wang HS; Cao GP; Ding JN; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):795-800. PubMed ID: 34289575
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation between EGFR mutation status and F
    Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
    Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of multiple metabolic and heterogeneity parameters of
    Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
    Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
    Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of positron emission tomography/computed tomography and chest thin-layer high-resolution computed tomography for evaluation of pulmonary nodules: Correlation with imaging features, maximum standardized uptake value, and pathology.
    Hou S; Lin X; Wang S; Shen Y; Meng Z; Jia Q; Tan J
    Medicine (Baltimore); 2018 Aug; 97(31):e11640. PubMed ID: 30075545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M; Lu D; Li X; Wang J; Zhang L; Yang P; Yang Y; Shen J
    Cancer Med; 2024 Sep; 13(18):e70216. PubMed ID: 39302034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical value of texture analysis of dual-time-point
    Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Semiquantitative parameters of
    Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of
    Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
    Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
    Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT radiomics analysis of lung cancers: Differentiation of squamous cell carcinoma from adenocarcinoma, a correlative study with FDG uptake.
    Tomori Y; Yamashiro T; Tomita H; Tsubakimoto M; Ishigami K; Atsumi E; Murayama S
    Eur J Radiol; 2020 Jul; 128():109032. PubMed ID: 32361604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
    Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
    Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Dynamic [
    Zhao Y; Lv T; Xu Y; Yin J; Wang X; Xue Y; Zhu G; Yu W; Wang H; Li X
    Mol Imaging Biol; 2024 Oct; 26(5):790-801. PubMed ID: 39174787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
    Wang D; Zhang M; Gao X; Yu L
    PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.